Anthropometric Measures and Severity of Gastroesophageal Reflux Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01954667

Enrollment

Registered

2013-10-07

Start date

2012-01-31

Completion date

2013-08-31

Last updated

2013-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease

Keywords

Gastroesophageal Reflux Disease; Anthropometric Measures; Leptin

Brief summary

evaluate the impact of different anthropometric measures on clinical and endoscopic severity of GERD and its relation to serum leptin.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Gastro esophageal reflux symptoms (e.g. heart burn, regurgitation, water brash or atypical symptoms such as hoarseness of voice, asthma and cough) * complete upper gastrointestinal endoscopy.

Exclusion criteria

* Receiving medication for reflux disease (including proton pump inhibitor, histamine type 2 receptors blocker, prokinetic agents) in the previous month. * Pregnant woman. * History of upper abdominal surgery. * Severe co-morbidity as cirrhosis, end-stage renal disease and heart failure.

Design outcomes

Primary

Measure	Time frame	Description
Impact of anthropometric measures on GERD	1 year	evaluate the impact of different anthropometric measures on clinical and endoscopic severity of GERD and its relation to serum leptin.

Countries

Egypt

Outcome results